Development and clinical assessment of novel biomarker drugs targeting SSAT1 for detection and therapeutic monitoring of glioblastoma

点击翻译按钮获取中文摘要

Glioblastoma multiforme (GBM) is the most common brain tumor in adults and is a death sentence for patients. The strikingly poor survival for patients with GBM (average survival 14- 16 months following diagnosis) is due in part to limited early detection methods and an absence of effective therapeutic options. The studies proposed would establish importantevidence for the use of Health Canada approved drugs such as amantadine and rimantadine as a safe, effective and affordable way to monitor GBM. The method is based on the overproduction of a key enzyme in GBM cells called spermine/ spermadine n-acetyl transferase (SSAT1). The increased SSAT1 expression in GBM results in increased metabolism of thedrug which is detected in the blood or urine of patients with GBM. Studies will provide evidence for the effectiveness of the drug amantadine, in detecting GBM in both cell culture and accepted rodent brain tumor models. Other drugs with similar chemical structure to amantadine will be examined in the cell culture and animal models to optimize the drugbiomarker for brain penetration and tumor cell activity. The studies will conclude with an initial assessment of the selected drug biomarker in patients with GBM to determine feasibility for clinical brain tumor applications. These bench to bedside studies will be utilized by our industrial partner, BioMark Diagnostics, to help improve identification and care for patientswith GB